Navigation Links
Hawaii receives funding for liver cancer research
Date:8/24/2011

HONOLULU---Two scientists from the University of Hawaii Cancer Center and The Queen's Medical Center have received a five-year $2.3 million grant from the National Cancer Institute to develop novel methods that can better detect liver cancer through the joint analysis of gene expression and imaging data of the liver. Co-leaders of the study are Gordon Okimoto, Ph.D., a research scientist at the UH Cancer Center, and Sandy Kwee, M.D., director of positron emission tomography (PET) research at The Queen's Medical Center.

Researchers will utilize positron emission tomography, or PET, to measure the levels of specific molecules in the body that have the potential to detect the presence of liver cancer. Additionally, they will profile global gene expression patterns in cancer-prone and normal tissue samples obtained from the imaged liver and create a catalog of novel cancer-related molecules that may aid in the early detection of liver cancer and serve as drug targets for the personalized treatment of the disease. "By improving our ability to detect liver disease and cancer at an earlier stage, we can greatly reduce deaths and improve patient outcomes," said Kwee.

Liver cancer is the third leading cause of cancer deaths in the world. Its incidence is rising in the U.S., particularly in Hawaii where incidence and death rates are the highest nationally. People infected with hepatitis viruses are more prone to developing liver cancer than the rest of the population, and some of the highest hepatitis rates in the world exist in Asia. Consequently, Asian immigrants who move to Hawaii are more likely to be carriers of the virus.

States Okimoto, "Competition for federal funding of cancer research is intense, and we are fortunate to receive this award. This grant represents collaborative research at its best and showcases the high level of science that we are conducting here in Hawaii." Fellow study investigators include Linda Wong, M.D., Brenda Hernandez, Ph.D., Naoky Tsai, M.D. and Owen Chan, M.D., Ph.D. , from the UH Cancer Center. This is the first funded research project of the Hawaii Cancer Consortium, an entity formed last year to promote collaboration among state partners engaged in translational cancer research. A primary goal of the Hawaii Cancer Consortium is to accelerate the translation of new findings in cancer research to the clinics for the benefit of patients in Hawaii, the Pacific Basin and beyond.


'/>"/>

Contact: Kellie Tormey
ktormey@cc.hawaii.edu
808-564-5814
University of Hawaii Cancer Center
Source:Eurekalert

Related biology news :

1. Insect scientists battle invasive species in Hawaii
2. Coffee berry borer in Hawaii and prospects for control
3. To be or not to be endangered? Listing of rare Hawaiian coral species called into question
4. US Forest Service and 2 universities team up to develop new ecosystems for Hawaiian forests
5. Scientists release first cultivated ohelo berry for Hawaii
6. Smithsonian scientists help create first frozen repository for Hawaiian coral
7. Creation of the first frozen repository for Hawaiian coral
8. Ancient Hawaiian glaciers reveal clues to global climate impacts
9. University of Hawaii completes 3-year investigation of military munitions sea disposal site
10. Hawaiian submarine canyons are hotspots of biodiversity and biomass for seafloor animal communities
11. University of Hawaii at Manoa researchers reveal ocean acidification at Station ALOHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: